Abstract
We developed a serum-free process in a closed system using culture cassettes and bags for large-scale and clinical-grade DC vaccination, accepted by the “Afssaps-French drug Agency”
(Tarte K. et al. Leukemia 2000; 14:2152 & patent)
. Intermediate mature DCs are generated from mononucleated cells obtained by mobilized leukapheresis, followed by Mo selection using adherence in specific cassettes (CLINIcell, Mabiol). Non-adherent cells are removed and Mo are cultured for 5 days (D) in X-VIVO15 medium (Cambrex) with 2% of human albumin, 100ng/ml of GM-CSF (Leukine, Berlex) and 25 ng/ml of IL-4 (CellGenix-Cellgen). At D5, immature DCs are harvested, pulsed with autologous tumor lysate (or peptides) for 4 h in X-VIVO15 medium + GM-CSF (100ng/ml) and maturation factors (TNF-α: 20ng/ml, CellGenix-CellGen, and PGE2: 100ng/ml; Prostine, Pharmacia). Maturation of DCs was allowed to proceed for 20 h with TNF-α and PGE2. Mo-conditioned media, or IL-6 as well as IL-1 are used for enhancing ex vivo DC maturation by different groups in spite of the fact that IL-6 has been described as a blocker of DC differentiation from CD34+ cells particularly in MM. We demonstrated that in our process, IL-6 is produced by activated Mo during their selection (mean= 378pg/mL, range 37–1219). The amount of the IL-6 released in the medium correlated with the % of CD14+ cells obtained at D5 (CD14<2.8%: mean IL-6=73.1 pg/mL; CD14>22.6%: mean IL-6=682.9 pg/mL), indicating that the intrinsic production of IL-6 is one major parameter of variability of the cellular product. By adding IL-6 from D1 to D5, the percentage of CD14+ cells at D5 was enhanced by a mean of 23-fold in samples from patients with MM (n=7) and 17-fold in ML (n=7). The modifications of other DCs markers including CD1a, CD 84 and CCR7 were modest. By using CNTO 328, an anti-IL-6 MAb (Centocor Inc) at 1–10μg/mL, we totally blocked the activity of added IL-6 and samples with high IL-6 intrinsic production, with a reduction of CD14+ cells at D5. In contrast, neither IL-6 nor CNTO 328 had any activity on terminal DC maturation after D5. IL-6 and CNTO328 are tested on DC functions. This means that in B-cell malignancies and other solid tumors with high levels of circulating IL-6: 1) anti-IL-6 treatment such as CNTO 328 may be associated with active immune therapy, including vaccinations; 2) mature and intermediate mature DCs are the only cells to be administered in vaccination programs because of a de-differentiation effect of immature DCs due to IL-6; 3) anti-IL-6 MAbs, particularly CNTO 328 could be added for ex vivo DC differentiation, instead of IL-6.mean % (range) of CD14+ cells at Day5
| samples . | MM . | ML . |
|---|---|---|
| Control | 2.9 (0.1–7.1) | 12.2 (0–44.8) |
| IL-6 (100ng/mL) | 20 (6–35) | 34.2 (0–71.4) |
| IL-6+CNTO328 1μg/mL | 2.8 (0.5–7.5) | 15.7 (0–45.6) |
| IL-6+CNTO328 10μg/mL | 0.4 (0–0.8) | 6.8 (0–20.3) |
| CNTO328 1μg/mL | 0.4 (0.1–0.7) | 6.5 (0–19.5) |
| CNTO328 10μg/mL | 0.2 (0–0.4) | 5.3 (0–15.3) |
| samples . | MM . | ML . |
|---|---|---|
| Control | 2.9 (0.1–7.1) | 12.2 (0–44.8) |
| IL-6 (100ng/mL) | 20 (6–35) | 34.2 (0–71.4) |
| IL-6+CNTO328 1μg/mL | 2.8 (0.5–7.5) | 15.7 (0–45.6) |
| IL-6+CNTO328 10μg/mL | 0.4 (0–0.8) | 6.8 (0–20.3) |
| CNTO328 1μg/mL | 0.4 (0.1–0.7) | 6.5 (0–19.5) |
| CNTO328 10μg/mL | 0.2 (0–0.4) | 5.3 (0–15.3) |
Author notes
Corresponding author
2005, The American Society of Hematology
2004
